Zionexa announces FDA acceptance of New Drug Application (NDA) for FES (Fluoroestradiol F18), a biomarker for targeted imaging in Metastatic Breast Cancer (MBC)
Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, [...]
EVENTS
SNMMI 2019
The SNMMI Clinical Trials Network is excited to sponsor a session at ASCO 2019 titled "Meet the Professors: Are We Ready for Prime Time in Molecular Imaging in Breast Cancer?"
